Retatrutide has emerged as one of the most closely watched investigational medicines in obesity research. Unlike conventional treatments that target a single metabolic pathway, retatrutide is designed to activate three hormone receptors—GLP-1, GIP, and glucagon. This multi-receptor mechanism has generated significant interest because clinical trials have reported substantial reductions in body weight, along with improvements